NMIBC treated with IL-15RαFc superagonist N-803 and BCG infusion скачать в хорошем качестве

NMIBC treated with IL-15RαFc superagonist N-803 and BCG infusion

Prof Sam Chang speaks to ecancer about the positive efficacy and safety phase 3 results in both CIS and papillary cohorts BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) after IL-15RαFc superagonist N-803 (Anktiva) and BCG infusion. He initially talks about the background of the study. Dr Chang notes that BCG induces trained immunity in the treatment of superficial bladder cancer by activating NK and T cell killing of bladder cancer cells. Furthermore, innate immune memory results in a prolonged durable complete response. Thus, the question is whether we can potentiate this innate immune response, perhaps through BCG + N-803. Dr Chang discusses the results of the trial saying that N-803 and BCG was safe and well-tolerated with no treatment-related or immune-related serious adverse events. The primary endpoints of both CIS and papillary disease were met with a complete response rate of 71% and 12-month disease-free rate of 57%, respectively. Durable responses were noted in both cohorts and the therapy resulted in significant avoidance of cystectomy with a cystectomy free rate of 92% and a 24-month cancer-specific survival of 99.5%. Given the observed strong efficacy, favourable adverse event profile, and mode of administration, N-803 represents a significant advance in the treatment option compared to existing therapies for BCG unresponsive CIS and papillary NMIBC. Sign up to ecancer for free to receive tailored email alerts for more videos like this. ecancer.org/account/register.php